Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.
about
Progression of cutaneous melanoma: implications for treatmentImmunologic functions as prognostic indicators in melanomaAdjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trialA multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfaIFN-α in the treatment of melanomaAdjuvant therapy: melanomaPro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease AfterThe Influence of HLA and KIR Genes on Malignant Melanoma Development and Progression.Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trialsFuture perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".HLA-DRB1,-DQA1 and -DQB1 allele and haplotype frequencies in female patients with early onset breast cancer.Melanoma & biomarkers of immunoresponsiveness
P2860
Q27001734-7262B009-A043-4DEE-A018-C3F60A90D24BQ33835011-F39D12A1-0C97-4483-B24F-6EA49BF1B779Q34289273-82213173-7E0E-48FD-B242-92B6DEEE91F1Q34335379-ABC2D774-A67F-46A2-879A-A027ACDAB9C8Q34387506-E7E0A5FC-6E68-426A-8E67-615FD9870156Q35020518-704B21F0-1E91-4634-9E64-1F531C4E35ABQ35572008-77E31DC3-3950-4319-9686-E1B88F22F247Q35636225-D7993986-58A2-42D0-94A8-C1D10D105D01Q35698637-67BD6701-2E2F-405B-8E6A-A9E6BCFA6C4AQ36346631-B6564AD2-17D3-43BA-91C2-498B4B7DC112Q39023067-DCE885BB-1DC9-47AB-8CCB-6241C560575BQ41881246-4DF26293-08CB-42E8-A607-5FE69FD6D53AQ43127268-0239D1F4-CBEB-4689-8AF5-034C6EB6F8F2Q51023647-4F564B2D-CE52-49D6-8203-47D4EB335FB0Q58234468-FD45513E-5556-4D01-9098-3878547A1E45
P2860
Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Correlation of molecular human ...... receiving adjuvant interferon.
@ast
Correlation of molecular human ...... receiving adjuvant interferon.
@en
Correlation of molecular human ...... receiving adjuvant interferon.
@nl
type
label
Correlation of molecular human ...... receiving adjuvant interferon.
@ast
Correlation of molecular human ...... receiving adjuvant interferon.
@en
Correlation of molecular human ...... receiving adjuvant interferon.
@nl
prefLabel
Correlation of molecular human ...... receiving adjuvant interferon.
@ast
Correlation of molecular human ...... receiving adjuvant interferon.
@en
Correlation of molecular human ...... receiving adjuvant interferon.
@nl
P2093
P2860
P356
P1433
P1476
Correlation of molecular human ...... receiving adjuvant interferon
@en
P2093
Alexandros Stratigos
Christine S Falk
Dimitrios Pectasides
Dimosthenis Tsoutsos
Helen Gogas
John M Kirkwood
Maria Spyropoulou-Vlachou
Vernon K Sondak
P2860
P304
P356
10.1002/CNCR.25211
P407
P577
2010-09-01T00:00:00Z